Viraferonpeg 150mcg Injection

Viraferonpeg 150mcg Injection is used in the treatment of chronic hepatitis C virus (HCV) infection.

Viraferonpeg 150mcg Injection is given as an injection by a qualified medical professional. You should continue to take it as long as your doctor advises it. The duration of treatment varies according to your need and response to treatment. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

Some common side effects of this medicine include headache, dizziness, insomnia, vomiting, and nausea. This medicine may reduce the number of blood cells in your blood, thereby, increasing the susceptibility to infections. Hence, inform your doctor if you notice fever, chills, rash, trouble breathing, unusual bleeding or bruising, and dark-colored urine. Regular blood tests are required to check your blood cells along with thyroid function, liver function, kidney function, and serum electrolyte levels.

Before taking it, tell your doctor if have liver, or kidney problems or have mental illness. You must inform your doctor if you notice mood changes, depression, vision changes, and suicidal thoughts while taking this medicine. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.

• Chronic hepatitis C virus (HCV) infection

Chronic hepatitis C virus (HCV) infection
Viraferonpeg 150mcg Injection helps control the infection and makes the immune system work better. This lowers your chances of getting complications and improves your quality of life. This medicine is always taken in combination with other antiretroviral medicines. It is not a cure and should neither be used to prevent HCV infection. It is important that you take this medicine as prescribed, following the dosage recommended by your doctor. Taking all doses in the right amount at the right times greatly increases the effectiveness of the medicine.

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Pegliton

• Abdominal pain
• Agitation
• Anxiety
• Blurred vision
• Cough
• Decreased appetite
• Decreased white blood cell count
• Depression
• Dizziness
• Dryness in mouth
• Fatigue
• Headache
• Impaired concentration
• Indigestion
• Insomnia (difficulty in sleeping)
• Nausea
• Nervousness
• Sore throat
• Stomatitis (Inflammation of the mouth)
• Viral infection
• Vomiting

Your doctor or nurse will give you this medicine. Kindly do not self administer.

Viraferonpeg 150mcg Injection modulates the body's immune system.

• Viraferonpeg 150mcg Injection helps treat chronic hepatitis C in adults.
• Do not drive or do anything that requires mental focus until you know how it affects you.
• Use a reliable contraceptive method to prevent pregnancy while you are taking this medicine and 4 months after stopping the treatment.
• Your doctor may get regular blood tests done to monitor your blood cells, liver and thyroid function, and lipid levels during treatment with this medicine.
• Inform your doctor immediately if you notice any signs of infection such as fever, sore throat or rash.
• Inform your doctor if you notice any changes in your behavior, mood or vision.

Peginterferon alfa-2b. Kenilworth, New Jersey: Schering Corporation; 2011. [Accessed 25 Jun. 2019] (online) Available from:

Medscape. Peginterferon alfa 2b. [Accessed 26 Jun. 2019] (online) Available from:

MedlinePlus. Peginterferon Alfa-2b. [Accessed 26 Jun. 2019] (online) Available from:

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006. Peginterferon Alfa. [Updated 2018 Dec 3]. [Accessed 18 Feb. 2020] (online) Available from: